Synthesis and Anti-cancer Activity of 3-substituted Benzoyl-4-substituted Phenyl-1H-pyrrole Derivatives. 2017

Xiaoping Zhan, and Weixi Qin, and Shuai Wang, and Kai Zhao, and Yuxuan Xin, and Yaolin Wang, and Qi Qi, and Zhenmin Mao
School of Pharmacy, Shanghai Jiaotong University, 800 Dongchuan Road, Shanghai 200240, China.

BACKGROUND Cancer is considered a major public health problem worldwide. OBJECTIVE The aim of this paper is to design and synthesis of novel anticancer agents with potent anticancer activity and minimum side effects. METHODS A series of pyrrole derivatives were synthesized, their anti-cancer activity against nine cancer cell lines and two non-cancer cell lines were evaluated by MTT assay, and their cell cycle progression were determined by flow cytometry analysis. RESULTS The study of the structure-activity relationships revealed that the introduction of the electron-donation groups at the 4th position of the pyrrole ring increased the anti-cancer activity. Among the synthesized compounds, specially the compounds bearing 3,4-dimethoxy phenyl at the 4th position of the pyrrole ring showed potent anti-cancer activity, cpd 19 was the most potent against MGC 80-3, HCT-116 and CHO cell lines (IC50s = 1.0-1.7 μM), cpd 21 was the most potent against HepG2, DU145 and CT-26 cell lines (IC50s = 0.5-0.9 μM), and cpd 15 was the most potent against A549 (IC50 = 3.6 μM). Moreover, these potent compounds showed weak cytotoxicity against HUVEC and NIH/3T3. Thus, the cpds 15, 19 and 21 show potential anti-cancer for further investigation. Furthermore, the flow cytometry analysis revealed that cpd 21 arrested the CT-26 cells at S phase, and induced the cell apoptosis. CONCLUSIONS Thus, these compounds with the potent anticancer activity and low toxicity have potential for the development of new anticancer chemotherapy agents.

UI MeSH Term Description Entries
D011758 Pyrroles Azoles of one NITROGEN and two double bonds that have aromatic chemical properties. Pyrrole
D003412 Cricetulus A genus of the family Muridae consisting of eleven species. C. migratorius, the grey or Armenian hamster, and C. griseus, the Chinese hamster, are the two species used in biomedical research. Hamsters, Armenian,Hamsters, Chinese,Hamsters, Grey,Armenian Hamster,Armenian Hamsters,Chinese Hamster,Chinese Hamsters,Grey Hamster,Grey Hamsters,Hamster, Armenian,Hamster, Chinese,Hamster, Grey
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D016466 CHO Cells CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells. CHO Cell,Cell, CHO,Cells, CHO
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Xiaoping Zhan, and Weixi Qin, and Shuai Wang, and Kai Zhao, and Yuxuan Xin, and Yaolin Wang, and Qi Qi, and Zhenmin Mao
February 2017, Chemistry & biodiversity,
Xiaoping Zhan, and Weixi Qin, and Shuai Wang, and Kai Zhao, and Yuxuan Xin, and Yaolin Wang, and Qi Qi, and Zhenmin Mao
January 2005, Farmaco (Societa chimica italiana : 1989),
Xiaoping Zhan, and Weixi Qin, and Shuai Wang, and Kai Zhao, and Yuxuan Xin, and Yaolin Wang, and Qi Qi, and Zhenmin Mao
December 2007, Journal of enzyme inhibition and medicinal chemistry,
Xiaoping Zhan, and Weixi Qin, and Shuai Wang, and Kai Zhao, and Yuxuan Xin, and Yaolin Wang, and Qi Qi, and Zhenmin Mao
May 1973, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
Xiaoping Zhan, and Weixi Qin, and Shuai Wang, and Kai Zhao, and Yuxuan Xin, and Yaolin Wang, and Qi Qi, and Zhenmin Mao
November 2012, Molecules (Basel, Switzerland),
Xiaoping Zhan, and Weixi Qin, and Shuai Wang, and Kai Zhao, and Yuxuan Xin, and Yaolin Wang, and Qi Qi, and Zhenmin Mao
November 1992, Farmaco (Societa chimica italiana : 1989),
Xiaoping Zhan, and Weixi Qin, and Shuai Wang, and Kai Zhao, and Yuxuan Xin, and Yaolin Wang, and Qi Qi, and Zhenmin Mao
January 1976, Journal of agricultural and food chemistry,
Xiaoping Zhan, and Weixi Qin, and Shuai Wang, and Kai Zhao, and Yuxuan Xin, and Yaolin Wang, and Qi Qi, and Zhenmin Mao
January 2001, Yao xue xue bao = Acta pharmaceutica Sinica,
Xiaoping Zhan, and Weixi Qin, and Shuai Wang, and Kai Zhao, and Yuxuan Xin, and Yaolin Wang, and Qi Qi, and Zhenmin Mao
May 1983, Journal of medicinal chemistry,
Xiaoping Zhan, and Weixi Qin, and Shuai Wang, and Kai Zhao, and Yuxuan Xin, and Yaolin Wang, and Qi Qi, and Zhenmin Mao
January 2015, Drug design, development and therapy,
Copied contents to your clipboard!